Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SI | P14410 | 2/20 | 0.50 |
| ▸ | GBA1 | P04062 | 4/20 | 0.46 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 5/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.34 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13172114 | 1.00 | SI (0.50) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL16315598 | 1.00 | SI (0.50) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL10186325 | 1.00 | SI (0.50) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL264749 | 1.00 | SI (0.50) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL13756984 | 1.00 | SI (0.50) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL13749980 | 1.00 | SI (0.50) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL12910796 | 0.97 | SI (0.54) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL17524259 | 0.97 | SI (0.54) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL13424330 | 0.97 | SI (0.54) | SIGBA1FUCA1MGAMOGA | |
| SCHEMBL15627023 | 0.97 | SI (0.54) | SIGBA1FUCA1MGAMOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3336091-A1 | IRAK4 INHIBITOR AND USE THEREOF | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-06-20 | — | — | EP | disclosed |
| US-9085535-B2 | Method and substances for the preparation of N-substituted pyridinium compounds | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-8580949-B2 | Enzymatic synthesis of carba-NAD | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-7638502-B2 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | PHARMASSET, INC. (US) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197462-A1 | Treatment of EBV and KHSV infection and associated abnormal cellular proliferation | UMPS, ENTPD5, TK1 | SI 654/4885GBA1 757/4885FUCA1 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.